Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC)
Conditions: Metastatic Esophageal Cancer; Metastatic Gastric Cancer Interventions: Drug: Single agent zimberelimab; Drug: Combination zimberelimab + domvanalimab Sponsors: Royal Marsden NHS Foundation Trust; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma Interventions: Device: Intermittent Oral-esophageal Tube Feeding; Device: nasogastric tube feeding Sponsors: People ' s Hospital of Zhengzhou University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer
Conditions: Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma Interventions: Drug: SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection; Drug: Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
Intermittent Oro-esophageal Tube Feeding in Late Dysphagia for Nasopharyngeal Carcinoma
Conditions: Dysphagia Interventions: Device: Intermittent Oral-esophageal Tube Feeding; Device: Nasogastric Tube Feeding; Behavioral: comprehensive rehabilitation therapy Sponsors: People ' s Hospital of Zhengzhou University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
A Study of MGC026 in Participants With Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer Interventions: Biological: MGC026 Dose Escalation; Biological: MGC026 Dose for Expansion Sponsors: MacroGenics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Other: no-Intervention Sponsors: Tianjin Medical University Cancer Institute and Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Other: non-intervention Sponsors: Tianjin Medical University Cancer Institute and Hospital; Chinese Academy of Medical Sciences; Sichuan Cancer Hospital and Research Institute Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Conditions: Biliary Tract Cancer; Breast Cancer; Cervical Cancer; Colon Cancer; Endometrial Cancer; Esophageal Cancer; Gastric Cancer; GastroEsophageal Cancer; Head and Neck Cancer; Hepatocellular Cancer; Non-small Cell Lung Cancer; Pancreatic Cancer; Prostate Cancer; Rectal Cancer; Renal Cancer; Thyroid Cancer Interventions: Drug: MDX2001 Sponsors: ModeX Therapeutics, An OPKO Health Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Conditions: Metastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Pancreatic Cancer; Ovarian Cancer; Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Renal Pelvis Cancer; Bladder Cancer Interventions: Drug: LY4101174 Sponsors: Eli Lilly and Company; Loxo Oncology, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Conditions: Lung Cancer, Nonsmall Cell; Esophageal Carcinoma Interventions: Drug: Camrelizumab; Drug: Thalidomide 50mg; Drug: Thalidomide 100mg; Drug: Thalidomide 200mg; Drug: Chemotherapy Sponsors: Henan Cancer Hospital; First Affiliated Hospital Xi ' an Jiaotong University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: Adebrelimab; Drug: Dalpiciclib 100mg; Drug: Dalpiciclib 150mg Sponsors: West China Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
A Study of the Tumor Microenvironment Affecting the Efficacy of Immunotherapy for Esophageal Cancer
Conditions: Esophageal Cancer Interventions: Other: no intervention Sponsors: Renmin Hospital of Wuhan University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
PRIORITY-CONNECT 2 Pilot Trial
Conditions: Liver Cancer; Pancreas Cancer; Oesophageal Cancer; Gastric Cancer; Colorectal Cancer Interventions: Behavioral: Preoperative Exercise; Behavioral: Postoperative Exercise; Dietary Supplement: Preoperative Nutrition; Dietary Supplement: Postoperative Nutrition; Behavioral: Preoperative Psychology; Behavioral: Postoperative Psychology; Other: Preoperative Nursing; Other: Postoperative Nursing; Other: Preoperative Peer Support Group; Other: Postoperative Peer Support Group; Other: Usual Care Sponsors: Surgical Outcomes Research Centre (SOuRCe) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial
Conditions: Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenoc...
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma
Conditions: Adebrelimab; Esophageal Cancer; Perioperative Period Interventions: Drug: adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil Sponsors: Xijing Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2024 Category: Research Source Type: clinical trials
